Becton Dickinson (BDX) just declared a total dividend of $1.05 per share, with an ex-dividend date of 9 September 2026 and payment scheduled for 30 September 2026, extending its long-running payout record.
At a share price of US$176.42, Becton Dickinson has seen short term pressure, with the 7 day share price return down 5.97% and the 30 day move down 2.75%. However, the 90 day share price return is up 20.64% and the 1 year total shareholder return is 20.75%, suggesting recent momentum has cooled after a stronger stretch earlier in the year.
Scan dividend-heavy healthcare alongside Becton Dickinson by reviewing a curated group of 6 dividend fortresses that combine income potential with established business models.
Becton Dickinson has handed investors a strong 12 month run and a fresh dividend, even as shorter term returns cooled. Does that balance of income and recent gains still leave enough upside in the current valuation?
Most Popular Narrative: 9.8% Undervalued
Becton Dickinson last closed at $176.42 compared with a widely followed fair value view near $196, which puts the recent dividend into a broader valuation story.
The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (>90% of revenue). This is expected to enable higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks directly support EPS growth.
Investors may want to understand what sits behind that split and buyback playbook. The narrative leans heavily on earnings power, a margin reset, and a sharply different share count path.
Result: Fair Value of $195.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the thesis around Becton Dickinson can be knocked off course if the Biosciences and Diagnostics separation runs into cost overruns, or if demand in China weakens.
Find out about the key risks to this Becton Dickinson narrative.
Another View On Becton Dickinson’s Valuation
The SWS DCF model points to a different conclusion, with Becton Dickinson at $176.42 compared with an estimated future cash flow value of $235.81, or about 25% below that figure. If cash generation really tracks those assumptions, this raises the question of whether the market is underestimating the long-term picture.
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed messages on Becton Dickinson’s value and risks rarely remain unresolved for long. Consider reviewing the full data promptly and weighing the 4 key rewards and 2 important warning signs.
Looking for more ideas beyond Becton Dickinson?
If you stop with Becton Dickinson, you miss the chance to spot other opportunities that could fit your goals just as well or even better.
- Expand your income focus by scanning a curated pool of reliable payers through the 6 dividend fortresses.
- Target value opportunities by reviewing the 33 high quality undervalued stocks that combine solid fundamentals with prices that may sit below intrinsic estimates.
- Strengthen capital protection by concentrating on companies from the 11 resilient stocks with low risk scores that aim to limit downside while still offering meaningful upside potential.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com